Brief: Shanghai Junshi Biosciences Says Phase III Clinical Study Of Toripalimab Met Primary Endpoint
25/09/2023 16:12
Sept 25 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* PHASE III CLINICAL STUDY OF TORIPALIMAB FOR FIRST-LINE
TREATMENT
OF MELANOMA MET PRIMARY ENDPOINT
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab